Inventiva S.A.

IVA • Biotechnology

$4.78

▼ -0.06 (-1.24%)

Precio actual

ResultadosÚltimo reporte: 31 dic 2025

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$3.05B

Crecimiento

-19.1%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Liquidez saludable · 3.15Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 dic 2025, 12:00 a.m. UTCÚltima actualización de earnings: 30 mar 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$4.78

Change-1.24%

Shares Out637.12M

Market Cap$3.05B

52W Range2.85 - 7.98

Beta0.88

P/E-2.70

P/S204.74

P/B-31.61

P/FCF-9.07

EV/Sales156.02

EV/EBITDA-5.46

Price$4.78

Change-1.24%

Shares Out637.12M

Market Cap$3.05B

52W Range2.85 - 7.98

Beta0.88

P/E-2.70

P/S204.74

P/B-31.61

P/FCF-9.07

EV/Sales156.02

EV/EBITDA-5.46

EV/FCF-6.91

Earnings Yield-37.06%

FCF Yield-11.03%

Dividend Yield0.00%

Gross Margin33.68%

Oper. Margin-29.21%

Profit Margin-75.88%

Debt/Eq-2.05

Current Ratio3.15

Quick Ratio3.15

Revenue 5Y-19.10%

Target$15.33

Target Upside220.71%

Target Median$13.00

Target Range12.00 - 24.00

Volume1.01M

Avg Volume445.10K

EPS Surprise-0.84

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

20/100

Por qué este puntaje▼

Liquidez saludable · 3.15Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

IVA

Analyst sentiment

Based on 8 analyst votes · 2026-09-05

88/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-15

Bajo

$12.00

Promedio

$16.50

Mediana

$15.00

Alto

$24.00

Resumen de la compañía

IPO: 7/10/2020

Industria: Biotechnology

P/B i: -31.61

Deuda / Patrimonio i: -2.05

Margen operativo: -2920.96%

Margen neto: -7587.80%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: -2.05

Ratio corriente: 3.15

Ratio rápido: 3.15

Estado: Good

🧾

No hay actividad interna

No hay transacciones internas recientes disponibles.

Sobre la compañía

Inventiva S.A.

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases. The company's most advanced experimental drug is Lanifibranor, which has successfully completed Phase IIb clinical trials for the treatment of NASH. Inventiva is also progressing with Odiparcil, an asset that has finished its Phase IIa clinical studies for addressing the MPS VI subtype disease. Beyond these lead candidates, Inventiva maintains a robust pipeline of earlier-stage research and development programs, notably in oncology and other therapeutic areas. The company has also established important strategic alliances, including a partnership with AbbVie focused on treatments for autoimmune diseases, and a collaboration with Boehringer Ingelheim International GmbH aimed at discovering novel therapies for idiopathic pulmonary fibrosis. Inventiva S.A. was established in 2011 and is headquartered in Daix, France.

Fuente - Link

Competidores

AVTX CRBU ENTA EPRX GNFT IVVD NAUT OBIO RNAC TNYA

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Inventiva Appoints Chris Benecchi as Chief Operating Officer

Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the appointment of Chris Benecchi as Chief Operating Officer. A proven biopharmaceutical leader with extensive experience in building organizations, preparing medicines for launch and integrating cross-functional operations, Mr. Benecchi will lead Inventiva's operational readiness as the Company approaches its pivotal NATiV3 Phase 3 topline study results of lanifibranor, in MASH, expected in Q4 2026, and prepares for potential commercialization.

GlobeNewsWire

Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives

Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Lanifibranor's potential lies in combination therapy, offering dual metabolic and anti-fibrotic benefits independent of weight loss, complementing GLP-1 and SGLT2 agents. Inventiva has secured sufficient liquidity through Q2 2027, with contingent access to further capital, and has strengthened governance ahead of the pivotal NATiV3 Phase 3 readout.

Seeking Alpha

Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press Release Dated July 29, 2026. The Company wishes to correct an error in the press release issued on July 29, 2026. On page 2, the potential proceeds for the Tranche C of the Debt Financing Transaction was mistakenly stated as €20 million. The correct figure is €55 million. All other information in the press release remains unchanged. As a result, the corrected version shall read as follows:

GlobeNewsWire

Inventiva Announces Preliminary Financial Results for the First Half of 2026¹

Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported certain preliminary financial results for the first half of 2026, including its cash, cash equivalents and revenues.

GlobeNewsWire

ADAR1 Capital Management LLC Sells 535,448 Shares of Inventiva S.A. Sponsored ADR $IVA

ADAR1 Capital Management LLC decreased its holdings in shares of Inventiva S.A. Sponsored ADR (NASDAQ: IVA) by 19.8% in the quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,174,398 shares of the company's stock after selling 535,448 shares during the

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-03-30	-0.23	-1.07	-0.84
2025-09-25	-0.41	-1.8931	-1.4831
2025-05-23	-0.47	-2.69286	-2.22286
2024-09-25	-0.56	-1.01416	-0.45416
2024-03-27	-0.4	-1.24663	-0.84663
2023-09-28	-1.26802	-1.43403	-0.16601
2023-03-29	-0.56812	-0.63572	-0.0676
2022-09-19	-0.90425	-0.75425	0.15
2022-03-03	-0.89589	-0.75851	0.13738
2021-09-20	-0.90995	-0.46442	0.44553
2020-12-31	-0.82056	-0.57473	0.24583
2020-09-16	-0.689	-0.32245	0.36655